Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Colonic Neoplasms 4Pancreatic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Colorectal Neoplasms 2Clinical Stage I Gastric Cancer AJCC v8 2Anus Neoplasms 2Tongue Neoplasms 1Sinonasal undifferentiated carcinoma 1Salivary Gland Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Adenocarcinoma 1PRETEXT I Hepatoblastoma 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Klatskin Tumor 1Keratosis, Actinic 1Hypopharyngeal Neoplasms 1Hepatoblastoma 1HIV Infections 1Gallbladder Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Epstein-Barr Virus Infections 1DNA Repair-Deficiency Disorders 1Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

Gemcitabine 18pembrolizumab 16Cisplatin 16Nivolumab 15atezolizumab 11durvalumab 9Specimen Handling 9Magnetic Resonance Spectroscopy 9Cystectomy 8Carboplatin 7Ipilimumab 6Fluorouracil 6avelumab 5Mitomycin 5sacituzumab govitecan 4erdafitinib 4enfortumab vedotin 4Surgical Procedures, Operative 4Immunoglobulin G 4Disulfides 4Biopsy 4tremelimumab 3cabozantinib 3Transurethral Resection of Bladder 3Surveys and Questionnaires 3Radiation 3Platinum 3Paclitaxel 3Leucovorin 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Urinary Bladder Neoplasms × dehydroftorafur × Clear all
NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡